Targeting SLAMF1 has been proposed as a therapeutic target for SLE since anti-SLAMF1 monoclonal antibody can reduce the T-B interaction, B cell production of IL6 and B cell differentiation into plasma cells (8). This evidence concerns the gene SLAMF1 and systemic lupus erythematosus.